Starwatch: the meeting of a star, the planet Mars and our moon
Following last week's conjunction between Regulus and Mars, the moon now gets in on the act. This meeting of a star, a planet and a moon takes place on 29 June. The chart shows the view looking west from London at 22:15 BST that day.
Red planet Mars has moved on from its close pass of blue-white star Regulus, giving enough space for a waxing crescent moon to slip in between them. The moon will be 4.7 days old, and heading towards its first quarter (half-moon) phase. Just over 22% of its visible surface will be illuminated.
From the moon, our nearest celestial neighbour, it takes the sunlight that bounces from its surface just 1.3 seconds to reach our eyes. For Mars, the fourth planet in our solar system, the light travel time from its surface is 15 minutes and 57 seconds. And for Regulus it takes light 79 years to reach us. So we see the moon as it appeared 1.3 seconds ago, Mars as it appeared 15 minutes and 57 seconds ago, and Regulus as it appeared 79 years ago.
The conjunction is easily visible from the southern hemisphere too, where it will appear in the north-north-west.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Huge boost in fight against colon cancer: Daily over-the-counter pill already in millions of medicine cabinets PREVENTS disease, study reveals
Taking a daily aspirin could help prevent bowel cancer in thousands of people at high risk, new research suggests. A major British study has found that even a low dose of the over-the-counter drug can halve the chances of developing the disease—offering protection with fewer side effects than previously thought. The findings are particularly important for people with Lynch syndrome—an inherited condition that affects about 175,000 people in the UK. It dramatically increases the lifetime risk of bowel cancer and other types of cancer. While the NHS already recommends aspirin for those with the condition, only around a quarter are currently taking it—often due to fears over side effects such as indigestion, ulcers and kidney problems. Researchers, led by Professor Sir John Burn of Newcastle University and funded by Cancer Research UK, found that a daily dose as low as 75 to 100mg—commonly known as 'baby aspirin'—was just as effective as the 600mg dose used in previous studies. 'The trial now tells us that aspirin can prevent bowel cancer at lower doses, minimising the chances of side-effects whilst offering vital protection,' said Professor Burn. He added: 'Too many people are missing out on a potentially life-changing opportunity to prevent cancer.' Lynch syndrome is thought to be responsible for around three per cent of bowel cancer cases in the UK. People with the condition are also more likely to be diagnosed with cancer before the age of 50. As well as bowel cancer, Lynch syndrome also significantly increases the risk of other cancers—including womb, ovarian and prostate cancer. One of those to benefit from the trial is Nick James, 46, who discovered he had the condition after undergoing genetic testing. 'Finding out I had a faulty gene that causes Lynch syndrome was extremely daunting,' he said. 'But taking part in this trial has given me hope that there's something that can reduce the chances of me and others developing cancer. Following the results, experts are now calling on the NHS to update its guidelines so more people at risk can benefit from the protective effects of aspirin. Professor Sir Burn said: 'We're now engaging with the regulators to change prescribing guidelines so that aspirin can be used more widely for people with a high risk of bowel cancer. 'We have a chance to give more people with Lynch syndrome protection which would reduce their fear of bowel cancer in the future.' Bowel cancer is on the rise in younger adults, even as rates fall among older generations. People born in 1990 are three times more likely to develop bowel cancer than those born in the 1950s, according to global research. In the UK, the disease kills nearly 17,000 people a year. While the vast majority of cases still occur in over-50s, around five per cent now affect adults aged 25 to 49—and that figure is steadily climbing. The main symptoms include changes in toilet habits, such as softer stools, diarrhoea or constipation. Going more or less often than usual, blood in the stool, or a feeling that you still need to go even after just going, can also be warning signs. Cancer Research UK estimates that more than half—54 per cent—of bowel cancer cases are preventable. Known risk factors include a diet low in fibre, eating too much red or processed meat, and obesity.
Reuters
an hour ago
- Reuters
UK pledges 1 billion pounds to build new biosecurity centre
LONDON, June 24 (Reuters) - Britain will invest 1 billion pounds ($1.35 billion) to establish a biosecurity centre, boosting its efforts to prevent a future pandemic by detecting high-risk animal diseases and other biological threats. The government said on Tuesday that the National Biosecurity Centre is expected to begin full operation in 2033/34 at a site in Surrey, southwest of London, which is already home to high-containment animal health laboratories. The centre is part of a broader National Security Strategy to be published later on Tuesday. "Farmers and food producers will now be better protected from diseases, our food security strengthened, and public health better safeguarded against future pandemics," British Environment Secretary Steve Reed said in a statement. The new centre will form part of a network of laboratories that will respond to biological security risks and threats, including from hostile nations, the government said. ($1 = 0.7426 pounds)
The Independent
2 hours ago
- The Independent
New ‘sponge on a string' trick could spare invasive cancer tests for ‘thousands of people'
Thousands of individuals currently monitored for food pipe cancer could be spared invasive diagnostic procedures thanks to a groundbreaking "sponge on a string" test, new research suggests. A study published in The Lancet medical journal indicates that this less invasive method could replace traditional endoscopies for more than half of patients with Barrett's oesophagus, a condition where stomach acid damages the lining of the food pipe, potentially leading to oesophageal cancer. Currently, the NHS offers regular monitoring for Barrett's oesophagus every two to five years, involving an endoscopy where a camera-equipped tube is passed into the oesophagus. This procedure, while effective, is invasive and can be uncomfortable for patients. However, researchers believe a new, less invasive capsule sponge test could offer a viable alternative for many. Already in use in some NHS hospitals for diagnosis, the test involves a patient swallowing a capsule attached to a string. Once swallowed, the capsule dissolves in the stomach, leaving a small sponge. After a few minutes, NHS staff pull the sponge back out via the string, collecting cells from the oesophageal lining for analysis. The new Lancet study, funded by Cancer Research UK, NHS England Cancer Alliance, and Innovate UK, involved 910 participants across 13 UK hospitals. The findings revealed that approximately 15 per cent of patients were identified as being at high risk of developing cancer, while a significant 54 per cent were classified as low risk. The study's authors concluded that the capsule sponge could effectively monitor patients with low-risk Barrett's oesophagus, replacing the need for regular endoscopies. Crucially, the test could be administered by nurses in GP practices, making it more accessible. Professor Peter Sasieni from Cancer Research UK's cancer prevention trials unit at Queen Mary University of London commented: "Our findings suggest that the capsule sponge could help stratify patients with Barrett's oesophagus by risk and that half of them will fall into the low-risk group. Given that the risk of these individuals progressing to dysplasia (abnormal cells) and then to oesophageal cancer is so low, it should be safe to replace their usual endoscopy with the capsule sponge." Professor Rebecca Fitzgerald from Cambridge added: "We are very excited by these results, which could lead to a test that is much more accessible and less operator dependent to improve standards for monitoring for patients with Barrett's across the NHS and beyond." Michelle Mitchell, chief executive of Cancer Research UK, also remarked on the breakthrough: "Survival rates for oesophageal cancer have remained unacceptably low for decades, with fewer than 20% of patients surviving for five or more years after diagnosis. Early detection is vital if we are to change this grim statistic." Ms Mitchell hailed the capsule sponge as "one of the most promising breakthroughs in early detection we have seen to date," adding that these new findings bring us closer to transforming diagnosis and treatment. She concluded: "If adopted widely, this innovative approach could spare significant numbers of people from discomfort and invasive endoscopies. By bringing this more accessible alternative into community care, we have the potential to save more lives."
